Research Paper Volume 13, Issue 5 pp 7147—7165

No difference in hepatocellular carcinoma risk in chronic hepatitis B patients treated with tenofovir vs entecavir: evidence from an updated meta-analysis

Propensity-score-matched meta-analysis comparing the effectiveness of TDF vs entecavir in reducing HCC risk. Note that this analysis is based on risk estimates from propensity-score-matched analyses. The squares represent risk estimate of each included study, with the area reflecting the weight assigned to the study. The horizontal line across each square represents 95% CI. The diamond represents the pooled risk estimate, with width representing 95% CI. TDF, tenofovir disoproxil fumarate; HCC, hepatocellular carcinoma; HR, hazard ratio; CI, confidence interval.

Figure 3. Propensity-score-matched meta-analysis comparing the effectiveness of TDF vs entecavir in reducing HCC risk. Note that this analysis is based on risk estimates from propensity-score-matched analyses. The squares represent risk estimate of each included study, with the area reflecting the weight assigned to the study. The horizontal line across each square represents 95% CI. The diamond represents the pooled risk estimate, with width representing 95% CI. TDF, tenofovir disoproxil fumarate; HCC, hepatocellular carcinoma; HR, hazard ratio; CI, confidence interval.